Study nudges Abbott's Duodopa towards US approval but Ph III pardoprunox is dumped
This article was originally published in Scrip
Abbott's announcement of positive efficacy results yesterday indicate that one of a brace of Phase III Parkinson's disease drugs it acquired with Solvay back in 2010 is on track for a US filing this year, but it the company has quietly abandoned development of the other one, pardoprunox.
You may also be interested in...
INFOGRAPHIC: In 2019, 10 blockbuster medicines booked combined sales of $92.5bn. This infographic examines those drugs that commanded the greatest revenues globally, and answers some key questions. Which therapeutic areas include the most lucrative blockbusters? Which companies enjoyed their spoils? And which drugs were new to the top 10 last year? It also takes a look at the position of these products on the all-important US market.
Fundraising in the life sciences sector has been booming even as firms in many other industries are struggling to stay in business. Goodwin’s David Mardle is upbeat about the sector’s ongoing prospects – although M&A deals are currently proving tricky to complete.
See how much the CEOs and R&D heads of the world’s biggest pharma companies get paid, and how those companies are performing.